RENE — ReNeuron Income Statement
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
Annual income statement for ReNeuron, fiscal year end - March 31st, GBP millions except per share, conversion factor applied.
R2019 March 31st | 2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | Interim Report | ARS | ARS | ARS | ARS |
| Standards: | — | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0.049 | 6.07 | 0.257 | 0.403 | 0.53 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 18.3 | 20.5 | 13.2 | 11.6 | 7.64 |
| Operating Profit | -18.3 | -14.4 | -12.9 | -11.2 | -7.12 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -17.2 | -13.9 | -13.4 | -11.1 | -6.66 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -14.3 | -11.4 | -11.3 | -9.69 | -5.41 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -14.3 | -11.4 | -11.3 | -9.69 | -5.41 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -14.3 | -11.4 | -11.3 | -9.69 | -5.41 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.441 | -0.349 | -0.291 | -0.17 | -0.095 |